Virtus ETF Advisers’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-17,112
| Closed | -$645K | – | 410 |
|
|
2021
Q1 | $645K | Buy |
17,112
+302
| +2% | +$7.53K | 0.27% | 117 |
|
|
2020
Q4 | $286K | Buy |
+16,810
| New | +$211K | 0.12% | 233 |
|
|
2019
Q2 | – | Sell |
-27,492
| Closed | -$368K | – | 452 |
|
|
2019
Q1 | $368K | Sell |
27,492
-3,935
| -13% | -$44.9K | 0.78% | 42 |
|
|
2018
Q4 | $292K | Buy |
31,427
+4,603
| +17% | +$54.8K | 0.05% | 117 |
|
|
2018
Q3 | $373K | Sell |
26,824
-19,183
| -42% | -$285K | 0.04% | 171 |
|
|
2018
Q2 | $727K | Buy |
46,007
+9,879
| +27% | +$172K | 0.64% | 86 |
|
|
2018
Q1 | $621K | Buy |
36,128
+18,757
| +108% | +$366K | 0.54% | 104 |
|
|
2017
Q4 | $381K | Buy |
17,371
+6,405
| +58% | +$206K | 0.48% | 65 |
|
|
2017
Q3 | $449K | Buy |
10,966
+1,003
| +10% | +$31.5K | 0.06% | 98 |
|
|
2017
Q2 | $300K | Buy |
9,963
+4,335
| +77% | +$135K | 0.04% | 124 |
|
|
2017
Q1 | $203K | Buy |
5,628
+540
| +11% | +$23.8K | 0.04% | 163 |
|
|
2016
Q4 | $255K | Sell |
5,088
-749
| -13% | -$39.4K | 0.08% | 136 |
|
|
2016
Q3 | $306K | Hold |
5,837
| – | – | 0.15% | 98 |
|
|
2016
Q2 | $241K | Sell |
5,837
-484
| -8% | -$21.1K | 0.18% | 103 |
|
|
2016
Q1 | $257K | Buy |
+6,321
| New | +$217K | 0.35% | 64 |
|
Virtus ETF Advisers's FPRX Position: Q2 2021 in Review
Virtus ETF Advisers sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 17,112 shares — an estimated $645K sold.
Virtus ETF Advisers first reported a position in FPRX in Q1 2016 and held it in 15 quarters. The position peaked at $727K in Q2 2018. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Virtus ETF Advisers reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Virtus ETF Advisers sold 17,112 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $645K.
- Virtus ETF Advisers first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 15 quarters.
- Virtus ETF Advisers's Five Prime Therapeutics, Inc. position peaked at $727K in Q2 2018.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.